Literature DB >> 16231197

Modelling the interaction of catecholamines with the alpha 1A adrenoceptor towards a ligand-induced receptor structure.

Gemma K Kinsella1, Isabel Rozas, Graeme W Watson.   

Abstract

Adrenoceptors are members of the important G protein coupled receptor family for which the detailed mechanism of activation remains unclear. In this study, we have combined docking and molecular dynamics simulations to model the ligand induced effect on an homology derived human alpha1A adrenoceptor. Analysis of agonist/alpha1A adrenoceptor complex interactions focused on the role of the charged amine group, the aromatic ring, the N-methyl group of adrenaline, the beta hydroxyl group and the catechol meta and para hydroxyl groups of the catecholamines. The most critical interactions for the binding of the agonists are consistent with many earlier reports and our study suggests new residues possibly involved in the agonist-binding site, namely Thr-174 and Cys-176. We further observe a number of structural changes that occur upon agonist binding including a movement of TM-V away from TM-III and a change in the interactions of Asp-123 of the conserved DRY motif. This may cause Arg-124 to move out of the TM helical bundle and change the orientation of residues in IC-II and IC-III, allowing for increased affinity of coupling to the G-protein.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16231197     DOI: 10.1007/s10822-005-7553-1

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  30 in total

1.  Three-dimensional representations of G protein-coupled receptor structures and mechanisms.

Authors:  Irache Visiers; Juan A Ballesteros; Harel Weinstein
Journal:  Methods Enzymol       Date:  2002       Impact factor: 1.600

2.  Constitutive activation of the beta2 adrenergic receptor alters the orientation of its sixth membrane-spanning segment.

Authors:  J A Javitch; D Fu; G Liapakis; J Chen
Journal:  J Biol Chem       Date:  1997-07-25       Impact factor: 5.157

Review 3.  G protein-coupled receptor drug discovery: implications from the crystal structure of rhodopsin.

Authors:  J Ballesteros; K Palczewski
Journal:  Curr Opin Drug Discov Devel       Date:  2001-09

Review 4.  Molecular basis of receptor/G-protein-coupling selectivity.

Authors:  J Wess
Journal:  Pharmacol Ther       Date:  1998-12       Impact factor: 12.310

5.  Structural instability of a constitutively active G protein-coupled receptor. Agonist-independent activation due to conformational flexibility.

Authors:  U Gether; J A Ballesteros; R Seifert; E Sanders-Bush; H Weinstein; B K Kobilka
Journal:  J Biol Chem       Date:  1997-01-31       Impact factor: 5.157

6.  Signal transduction by a 5-HT2 receptor: a mechanistic hypothesis from molecular dynamics simulations of the three-dimensional model of the receptor complexed to ligands.

Authors:  D Zhang; H Weinstein
Journal:  J Med Chem       Date:  1993-04-02       Impact factor: 7.446

7.  Constitutively active mutants of the alpha 1B-adrenergic receptor: role of highly conserved polar amino acids in receptor activation.

Authors:  A Scheer; F Fanelli; T Costa; P G De Benedetti; S Cotecchia
Journal:  EMBO J       Date:  1996-07-15       Impact factor: 11.598

8.  Ligand-induced domain motion in the activation mechanism of a G-protein-coupled receptor.

Authors:  X Luo; D Zhang; H Weinstein
Journal:  Protein Eng       Date:  1994-12

9.  A reciprocal mutation supports helix 2 and helix 7 proximity in the gonadotropin-releasing hormone receptor.

Authors:  W Zhou; C Flanagan; J A Ballesteros; K Konvicka; J S Davidson; H Weinstein; R P Millar; S C Sealfon
Journal:  Mol Pharmacol       Date:  1994-02       Impact factor: 4.436

10.  Related contribution of specific helix 2 and 7 residues to conformational activation of the serotonin 5-HT2A receptor.

Authors:  S C Sealfon; L Chi; B J Ebersole; V Rodic; D Zhang; J A Ballesteros; H Weinstein
Journal:  J Biol Chem       Date:  1995-07-14       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.